Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital in connection with the sale of Assessio
Mandate

Vinge advises Main Capital in connection with the sale of Assessio

September 01, 2023 M&A

Vinge advises Main Capital V (“Main Capital”) in connection with the sale of Assessio International Holding 2 AB and its subsidiaries (“Assessio”)

Assessio is a SaaS company specialising in strategic HR and develops tests and tools within work psychology. Their tools can, among other things, help organisations predict who has the best potential to succeed in a role, find future leaders in the organisation and help define their organisational culture and match it with the individuals’ values.

Main Capital acquired Assessio in 2019, and since then, Assessio has doubled its revenue and is today the leading player in talent assessment in both the Nordics and Benelux, with over 1,800 customers across a wide range of industries.

Vinge’s team mainly consisted of Jonas Johansson, Filip Öhrner, Maria Dahlin Kolvik, Per Kling, Stina Bengtsson, Gustav Persson, Johan Gavelin, Sophie Böje, Alexander Rüdén and Anna Ekdahl Roos.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025